Detail akcie Sinovac Bio online

Business Summary: Sinovac Biotech Ltd (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, hand foot and mouth disease (HFMD), seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Sinovac Biotech Ltd revenues decreased 14% to $121.3M. Net loss applicable to common stockholders totaled $10.9M vs. income of $14M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Other income, net decrease of 51% to $166.5M (income), G/L on Sale of Tangible & Intangible F increase from $312K to $5.4M (expense).